Inspire Denufosol Phase II Cystic Fibrosis Data Support Early Use, Firm Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Inspire is hoping to expedite moving its cystic fibrosis therapy, INS-37217, into Phase III following better-than-expected Phase II results.